Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Healthtrust
Cerilliant
McKinsey
QuintilesIMS
Fuji
UBS
US Department of Justice
Chubb

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,960,564

« Back to Dashboard

Which drugs does patent 6,960,564 protect, and when does it expire?

Patent 6,960,564 protects ERAXIS and is included in one NDA.

This patent has twenty-one patent family members in seventeen countries.
Summary for Patent: 6,960,564
Title: Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Abstract:Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
Inventor(s): Milton; Nathaniel (Indianapolis, IN), Moder; Kenneth Philip (West Lafayette, IN), Sabatowski; James Lawrence (Holland, MI), Sweetana; Stephanie Ann (Bloomington, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/942,431
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Use;

Drugs Protected by US Patent 6,960,564

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF FUNGAL INFECTIONS ➤ Sign Up
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF FUNGAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,960,564

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,444 Echinocandin pharmaceutical formulations containing micelle-forming surfactants ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
Boehringer Ingelheim
AstraZeneca
Farmers Insurance
Queensland Health
Daiichi Sankyo
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.